|
[1]
|
Hyppönen, E., Mulugeta, A., Zhou, A., et al. (2019) A Data-Driven Approach for Studying the Role of Body Mass in Multiple Diseases: A Phenome-Wide Registry-Based Case-Control Study in the UK Biobank. The Lancet Digital Health, 1, e116-e126. [Google Scholar] [CrossRef]
|
|
[2]
|
Chooi, Y.C., Ding, C. and Magkos, F. (2019) The Epidemiology of Obesity. Metabolism, 92, 6-10. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Mann, T., Tomiyama, A.J., Westling, E., et al. (2007) Medicare’s Search for Effective Obesity Treatments: Diets Are Not the Answer. American Psychologist, 62, 220-233. [Google Scholar] [CrossRef]
|
|
[4]
|
Wadden, T.A., Tsai, A.G. and Tronieri, J.S. (2019) A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL-IBT Program. Obesity (Silver Spring), 27, 1562-1566. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Yumuk, V., Tsigos, C., Fried, M., et al. (2015) European Guidelines for Obesity Management in Adults. Obesity Facts, 8, 402-424. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Garvey, W.T., Mechanick, J.I., Brett, E.M., et al. (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice, 22, 1-203. [Google Scholar] [CrossRef]
|
|
[7]
|
Pilitsi, E., Farr, O.M., Polyzos, S.A., et al. (2019) Pharmacotherapy of Obesity: Available Medications and Drugs under Investigation. Metabolism, 92, 170-192. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Drucker, D.J. and Nauck, M.A. (2006) The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes. The Lancet, 368, 1696-1705. [Google Scholar] [CrossRef]
|
|
[9]
|
Scott, L.J. (2015) Liraglutide: A Review of Its Use in the Management of Obesity. Drugs, 75, 899-910. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Baggio, L.L. and Drucker, D.J. (2007) Biology of Incretins: GLP-1 and GIP. Gastroenterology, 132, 2131-2157. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Secher, A., Jelsing, J., Baquero, A.F., et al. (2014) The Arcuate Nucleus Mediates GLP-1 Receptor Agonist Liraglutide-Dependent Weight Loss. The Journal of Clinical Investigation, 124, 4473-4488. [Google Scholar] [CrossRef]
|
|
[12]
|
Blundell, J., Finlayson, G., Axelsen, M., et al. (2017) Effects of Once-Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects with Obesity. Diabetes, Obesity and Metabolism, 19, 1242-1251. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Bays, H., Pi-Sunyer, X., Hemmingsson, J.U., et al. (2017) Liraglutide 3.0 mg for Weight Management: Weight-Loss Dependent and Independent Effects. Current Medical Research and Opinion, 33, 225-229. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Astrup, A., Carraro, R., Finer, N., et al. (2012) Safety, Tolerability and Sustained Weight Loss over 2 Years with the Once-Daily Human GLP-1 Analog, Liraglutide. International Journal of Obesity (London), 36, 843-854. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Lean, M.E., Carraro, R., Finer, N., et al. (2014) Tolerability of Nausea and Vomiting and Associations with Weight Loss in a Randomized Trial of Liraglutide in Obese, Non-Diabetic Adults. International Journal of Obesity (London), 38, 689-697. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015) A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England Journal of Medicine, 373, 11-22. [Google Scholar] [CrossRef]
|
|
[17]
|
Kolotkin, R.L., Fujioka, K., Wolden, M.L., et al. (2016) Improvements in Health-Related Quality of Life with Liraglutide 3.0 mg Compared with Placebo in Weight Management. Clinical Obesity, 6, 233-242. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Hoda, K., Victor, C., Houssam, H., et al. (2020) GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones and Regional Body Fat Stores in Adults with Obesity. The Journal of Clinical Endocrinology & Metabolism, 105, 1552-1563. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 375, 311-322. [Google Scholar] [CrossRef]
|
|
[20]
|
Yan, J.H., Yao, B., Kuang, H.Y., Yang, X.B., et al. (2019) Liraglutide, Sitagliptin and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients with Type 2 Diabetes Mellitus and NAFLD. Hepatology, 69, 2414-2426. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Ishii, S., Nagaia, Y., Sada, Y., Fukuda, H., et al. (2019) Liraglutide Reduces Visceral and Intrahepatic Fat without Significant Loss of Muscle Mass in Obese Patients with Type 2 Diabetes: A Prospective Case Series. Journal of Clinical Medicine Research, 11, 219-224. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Bizino, M.B., Jazet, I.M., et al. (2020) Placebo-Controlled Randomised Trial with Liraglutide on Magnetic Resonance Endpoints in Individuals with Type 2 Diabetes: A Pre-Specified Secondary Study on Ectopic Fat Accumulation. Diabetologia, 63, 65-74. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Tang, A., Rabasa-Lhoret, R., et al. (2015) Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients with Type 2 Diabetes: A Randomized Trial. Diabetes Care, 38, 1339-1346. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Decara, J., Arrabal, S., Beiroa, D., et al. (2016) Antiobesity Efficacy of GLP-1 Receptor Agonist Liraglutide Is Associated with Peripheral Tissue Specific Modulation of Lipid Metabolic Regulators. Biofactors, 42, 600-611. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Li, Z., Liang, Y., Xia, N., et al. (2017) Liraglutide Reduces Body Weight by Upregulation of Adenylate Cyclase 3. Nutrition & Diabetes, 7, e265. [Google Scholar] [CrossRef] [PubMed]
|